➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

McKesson
Mallinckrodt
Colorcon
Moodys
Baxter
AstraZeneca

Last Updated: September 22, 2021

DrugPatentWatch Database Preview

Details for Patent: 8,940,718


Email this page to a colleague

« Back to Dashboard

Which drugs does patent 8,940,718 protect, and when does it expire?

Patent 8,940,718 protects EPCLUSA and VOSEVI and is included in three NDAs.

Protection for EPCLUSA has been extended six months for pediatric studies, as indicated by the *PED designation in the table below.

This patent has one hundred and twenty-five patent family members in thirty-eight countries.

Summary for Patent: 8,940,718
Title:Antiviral compounds
Abstract: The disclosure is related to anti-viral compounds, compositions containing such compounds, and therapeutic methods that include the administration of such compounds, as well as to processes and intermediates useful for preparing such compounds.
Inventor(s): Bacon; Elizabeth M. (Burlingame, CA), Cottell; Jeromy J. (Redwood City, CA), Katana; Ashley Anne (San Mateo, CA), Kato; Darryl (San Francisco, CA), Krygowski; Evan S. (Washington, DC), Link; John O. (San Francisco, CA), Taylor; James (San Mateo, CA), Tran; Chinh Viet (San Mateo, CA), Martin; Teresa Alejandra Trejo (Union City, CA), Yang; Zheng-Yu (Palo Alto, CA), Zipfel; Sheila (San Mateo, CA)
Assignee: Gilead Pharmasset LLC (Foster City, CA)
Application Number:13/679,874
Patent Claim Types:
see list of patent claims
Compound; Composition; Use;

Recent additions to Drugs Protected by US Patent 8,940,718

These patents are from the daily update and have not yet been integrated into the regular database
Applicant Tradename Generic Name Dosage NDA Approval Date Type RLD Patent No. Product Substance Delist Req. Patent Expiration Usecode Patented / Exclusive Use
Gilead Sciences Inc EPCLUSA sofosbuvir; velpatasvir PELLETS 214187 Jun 10, 2021 RX Yes ⤷  Free Forever Trial Y Y ⤷  Free Forever Trial U-1470 FOR THE TREATMENT OF HEPATITIS C
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >Type >RLD >Patent No. >Product >Substance >Delist Req. >Patent Expiration >Usecode >Patented / Exclusive Use

Drugs Protected by US Patent 8,940,718

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Submissiondate
Gilead Sciences Inc EPCLUSA sofosbuvir; velpatasvir PELLETS;ORAL 214187-001 Jun 10, 2021 RX Yes No ⤷  Free Forever Trial ⤷  Free Forever Trial Y Y FOR THE TREATMENT OF HEPATITIS C ⤷  Free Forever Trial
Gilead Sciences Inc EPCLUSA sofosbuvir; velpatasvir PELLETS;ORAL 214187-002 Jun 10, 2021 RX Yes Yes ⤷  Free Forever Trial ⤷  Free Forever Trial Y Y FOR THE TREATMENT OF HEPATITIS C ⤷  Free Forever Trial
Gilead Sciences Inc EPCLUSA sofosbuvir; velpatasvir TABLET;ORAL 208341-002 Mar 19, 2020 RX Yes No ⤷  Free Forever Trial ⤷  Free Forever Trial Y ⤷  Free Forever Trial
Gilead Sciences Inc EPCLUSA sofosbuvir; velpatasvir TABLET;ORAL 208341-001 Jun 28, 2016 RX Yes Yes ⤷  Free Forever Trial ⤷  Free Forever Trial Y ⤷  Free Forever Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Patented / Exclusive Use >Submissiondate

International Family Members for US Patent 8,940,718

Country Patent Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Argentina 083711 ⤷  Free Forever Trial
Australia 2011328980 ⤷  Free Forever Trial
Australia 2012318253 ⤷  Free Forever Trial
Australia 2015243078 ⤷  Free Forever Trial
>Country >Patent Number >Estimated Expiration >Supplementary Protection Certificate >SPC Country >SPC Expiration

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Medtronic
Mallinckrodt
Merck
McKesson
McKinsey
Harvard Business School

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.